Maravai LifeSciences Holdings, Inc. $MRVI Stock Holdings Increased by 12 West Capital Management LP

Key Points

• 12 West Capital Management LP increased its stake in Maravai LifeSciences by 8.0%, acquiring an additional 930,000 shares, bringing its total holdings to 12,521,335 shares.
• Maravai LifeSciences' stock experienced a decline of 2.1% with a current market price of $2.37, while its price targets from several analysts have been reduced significantly.
• Institutional investors and hedge funds own over 50% of Maravai LifeSciences' stock, indicating strong institutional interest in the company.

12 West Capital Management LP raised its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 8.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,521,335 shares of the company's stock after acquiring an additional 930,000 shares during the quarter. Maravai LifeSciences makes up about 4.1% of 12 West Capital Management LP's investment portfolio, making the stock its 8th largest holding. 12 West Capital Management LP owned 4.92% of Maravai LifeSciences worth $27,672,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Deutsche Bank AG increased its stake in shares of Maravai LifeSciences by 67.6% in the 1st quarter. Deutsche Bank AG now owns 2,072,239 shares of the company's stock valued at $4,580,000 after acquiring an additional 835,600 shares in the last quarter. SG Americas Securities LLC boosted its stake in Maravai LifeSciences by 2,005.9% in the first quarter. SG Americas Securities LLC now owns 695,907 shares of the company's stock worth $1,538,000 after buying an additional 662,861 shares in the last quarter. CenterBook Partners LP boosted its stake in shares of Maravai LifeSciences by 67.2% during the first quarter. CenterBook Partners LP now owns 1,357,600 shares of the company's stock valued at $3,000,000 after purchasing an additional 545,674 shares during the period. Monaco Asset Management SAM lifted its position in Maravai LifeSciences by 186.9% during the first quarter. Monaco Asset Management SAM now owns 835,865 shares of the company's stock valued at $1,847,000 after buying an additional 544,501 shares during the period. Finally, Tejara Capital Ltd bought a new position in shares of Maravai LifeSciences during the first quarter valued at $1,199,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Trading Down 2.6%

Shares of MRVI stock traded down $0.07 during trading hours on Monday, hitting $2.45. 537,807 shares of the company's stock traded hands, compared to its average volume of 2,306,658. The company has a quick ratio of 4.49, a current ratio of 5.16 and a debt-to-equity ratio of 0.68. The stock's 50 day simple moving average is $2.49 and its 200 day simple moving average is $2.35. The stock has a market cap of $624.36 million, a PE ratio of -1.81 and a beta of 0.29. Maravai LifeSciences Holdings, Inc. has a 12 month low of $1.66 and a 12 month high of $9.50.

Analyst Ratings Changes

Several research firms have recently weighed in on MRVI. Robert W. Baird cut their target price on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Craig Hallum dropped their price objective on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada reduced their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $5.22.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.